Albrecht, Thomas
Ukrow, Antonia
Werk, Michael
Tepe, Gunnar
Zeller, Thomas
Meyer, Dirk-Roelfs
Kutschera, Maren
Speck, Ulrich
Waliszewski, Matthias
Article History
Received: 10 October 2018
Accepted: 28 November 2018
First Online: 11 December 2018
Change Date: 12 March 2019
Change Type: Correction
Change Details: In their recently published pooled analysis of four drug-coated balloon (DCB) studies, which focused on the impact of patient and lesion characteristics on LLL at 6 months (Albrecht T et al. Cardiovasc Intervent Radiol. 2018 Dec 11. <ExternalRef><RefSource>https://doi.org/10.1007/s00270-018-2137-3</RefSource><RefTarget Address="10.1007/s00270-018-2137-3" TargetType="DOI"/></ExternalRef>), the authors reported slightly inaccurate 2-year mortality rates.
Compliance with Ethical Standards
:
: In the previously conducted randomized controlled trials that provided the raw data for this analysis, TA, MW, TZ and GT received research grants from Medtronic, whereas TA, TZ and GT obtained research funding from B.Braun. MWW is a full-time employee of the Medical Scientific Affairs department of B.Braun Melsungen AG.
: All studies were approved by the Federal Institute for Drugs and Medical Devices, by the Federal Agency for Radiation Protection and by all relevant ethics committees of participating centers. Patients gave written informed consent prior to inclusion. An independent critical event committee was installed to adjudicate event rates. Blinded quantitative angiographic analysis was conducted by an independent core lab. All trials were registered with the US National Institutes of Health prior to recruitment. This trial was conducted in accordance with the updated Declaration of Helsinki and other relevant guidance.
: Informed consent was obtained from all individual participants included in the study.